Aion Therapeutic Inc. has filed several plant-based patents with the USPTO.
Another private player in the psychedelics industry moves to go public. Prospectus available on SEDAR.
A major IPO can be expected to attract a lot of new attention (and capital) to the psychedelic drug industry.
Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.
Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.
Certain large Mydecine shareholders have entered into a voluntary lock-up, covering 52,908,420 common shares.
Wall Street and Silicon Valley investors recently piled into a $30-million psychedelics fund-raising initiative.
Field Trip Psychedelics completes its qualifying transaction and definitive agreement with RTO partner.